Akoya Biosciences (NASDAQ:AKYA - Get Free Report) is set to post its quarterly earnings results after the market closes on Thursday, November 14th. Analysts expect Akoya Biosciences to post earnings of ($0.19) per share for the quarter. Persons interested in participating in the company's earnings conference call can do so using this link.
Akoya Biosciences (NASDAQ:AKYA - Get Free Report) last announced its quarterly earnings data on Monday, August 5th. The company reported ($0.27) EPS for the quarter, hitting analysts' consensus estimates of ($0.27). The firm had revenue of $23.16 million during the quarter, compared to analyst estimates of $23.61 million. Akoya Biosciences had a negative return on equity of 126.38% and a negative net margin of 64.74%. During the same period last year, the company earned ($0.51) earnings per share. On average, analysts expect Akoya Biosciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Akoya Biosciences Stock Up 4.9 %
Shares of NASDAQ AKYA opened at $3.24 on Thursday. Akoya Biosciences has a 1 year low of $1.88 and a 1 year high of $6.31. The firm's 50-day moving average is $2.81 and its 200-day moving average is $2.67. The company has a current ratio of 2.73, a quick ratio of 1.98 and a debt-to-equity ratio of 3.43. The firm has a market capitalization of $160.38 million, a PE ratio of -2.63 and a beta of 1.34.
Analyst Ratings Changes
A number of analysts have commented on AKYA shares. Craig Hallum lowered their target price on shares of Akoya Biosciences from $7.50 to $7.00 and set a "buy" rating for the company in a report on Tuesday, August 6th. Piper Sandler dropped their price objective on Akoya Biosciences from $6.00 to $4.00 and set an "overweight" rating for the company in a report on Tuesday, August 13th. Morgan Stanley cut Akoya Biosciences from an "overweight" rating to an "equal weight" rating and reduced their target price for the stock from $4.00 to $3.00 in a report on Tuesday, August 6th. JPMorgan Chase & Co. lowered Akoya Biosciences from an "overweight" rating to a "neutral" rating in a research report on Tuesday, August 6th. Finally, BTIG Research downgraded shares of Akoya Biosciences from a "buy" rating to a "neutral" rating in a research report on Tuesday, August 6th. Four analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $6.56.
Check Out Our Latest Stock Report on AKYA
About Akoya Biosciences
(
Get Free Report)
Akoya Biosciences, Inc, a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow.
Featured Stories
Before you consider Akoya Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Akoya Biosciences wasn't on the list.
While Akoya Biosciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
